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Background:  Acute  hyperglycemia  (AH)  after  the onset  of acute  myocardial  infarction  (AMI)  is  a  manifes-
tation  of transient  abnormal  glucose  metabolism  that may  reﬂect  AMI  severity,  and thus  be a  predictor  of
poor prognosis.  However,  it remains  unknown  whether  AH  may  predict  development  of de  novo  diabetes
mellitus  (dn-DM)  in  non-diabetic  AMI  patients.
Methods and results:  Among  AMI  patients  registered  in  the  Osaka  Acute  Coronary  Insufﬁciency  Study
between  1998  and  2007,  we  investigated  hospital  records  of 1493  patients  who  had  an  admission  glycated
hemoglobin  A1c  (HbA1c)  level  of  ≤6.0%  and  were  subjected  to  glycometabolic  proﬁling  after  survival
discharge.  dn-DM  was  deﬁned  as  initiation  of  diabetic  medication  or  documentation  of an HbA1c level  of
≥6.5% during  the  5-year  follow-up  period.  AH,  deﬁned  as  an  admission  serum  glucose  level  of ≥200  mg/dl,
was  observed  in 133  (8.9%)  patients.  dn-DM  development  was more  frequent  in post-AMI  patients  with
AH than  those  without  [24.8%  vs  12.0%,  adjusted  hazard  ratio  (HR)  1.776,  p  =  0.021],  particularly  among
patients  with  an  HbA1c  of  <5.6%  on  admission.  Treatment  with  angiotensin-converting  enzyme  inhibitors
or  angiotensin  receptor  blockers  was  associated  with  a  reduced  incidence  of  dn-DM  in  patients  with  AH
(adjusted  HR  0.397,  p  = 0.031).
Conclusion:  Admission  AH  was  a predictor  of dn-DM  in  non-diabetic  post-AMI  patients.  Renin–
angiotensin  system  inhibitors  were  associated  with  reduced  incidence  of dn-DM  in  post-AMI  patients
with  AH.
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Numerous studies have identiﬁed an association between dia-
etes mellitus (DM) and the incidence or development of coronary
eart disease (CHD), including acute myocardial infarction (AMI)
1–8]. It has been reported that patients with a recent myocardial
nfarction have a higher annual incidence rate of impaired fas-
ing glucose and DM than the general population [9], suggesting
hat AMI  may  be a DM risk equivalent [10]. In addition, evidence
uggests that post-AMI patients who develop DM are at high risk
f adverse events [10]. As these ﬁndings indicate that diabetic
ndividuals with CHD have worse morbidity and mortality than
on-diabetic CHD patients [11,12], risk stratiﬁcation in the clini-
al setting for the development of de novo DM (dn-DM) is expected
o improve mortality in post-AMI patients. To date, however, few
redictive markers for the development of dn-DM after AMI  have
een identiﬁed.
In the present study, we investigated the clinical impact of acute
yperglycemia (AH) on the development of dn-DM and pharma-
ological modiﬁcation in post-AMI patients. AH, which is often
bserved in both non-diabetic and diabetic AMI  patients [13,14],
s considered to be a manifestation of transient abnormal glucose
etabolism that is induced during the acute phase of myocardial
nfarction (MI) [13–18]. Although a few studies have reported a
elationship between AH and adverse clinical outcomes after AMI,
he association between AH and development of dn-DM after sur-
ival discharge for AMI  was unclear. Thus, in the present study, we
xamined a hypothesis that AH is a predictor for the development
f dn-DM in post-AMI patients by reviewing the database of the
saka Acute Coronary Insufﬁciency Study (OACIS) registry.
ethods
he OACIS registry
The OACIS is a prospective multicenter observational study
nvolving 25 hospitals from the Osaka region of Japan that record
emographic, procedural, and outcome data, and collect blood sam-
les from AMI  patients. The OACIS is registered with the University
ospital Medical Information Network Clinical Trials Registry,
apan (ID: UMIN000004575). A detailed description of the OACIS
as been published elsewhere [19–22]. The OACIS study protocol
as approved by the ethical committee of each participating hos-
ital and written informed consent was provided by all patients at
he time of registration. The OACIS registry is designed to collect
niform prospective data that can be used to assess clinical vari-
bles, therapeutic procedures, and clinical events in AMI  patients.
he diagnosis of AMI required 2 of the following 3 criteria to be met:
1) a history of central chest pressure, pain, or tightness lasting for
0 min  or more, (2) ST-segment elevation greater than 0.1 mV  in at
east 1 limb lead or 2 precordial leads, and (3) an increase of serum
reatine kinase (CK) concentration to more than twice the upper
imit of normal. All patients presenting within one week after the
nset of AMI  were registered prospectively after the diagnosis of
MI was made.
tudy population
Of 8025 consecutive AMI  patients registered in the OACIS
etween April 1998 and December 2007, patients who  fulﬁlled
he following criteria were enrolled in the present study: (1) non-
iabetic patients discharged alive; (2) assessment of development
f dn-DM during a ﬁve-year follow-up period; and (3) plasma
lucose and glycated hemoglobin A1c (HbA1c) levels were mea-
ured on admission. To minimize the inﬂuence of pre-existing DM
n hyperglycemia, we excluded patients with an HbA1c > 6.0% onology 63 (2014) 274–280 275
admission. A total of 1493 patients fulﬁlled the inclusion criteria.
These patients were divided into 2 groups according to whether
they had a plasma glucose concentration of ≥200 mg/dl (AH group;
n = 133) or <200 mg/dl (non-AH group; n = 1360) on admission.
The AH and non-AH groups were further divided into subgroups
based on treatment with angiotensin-converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs) at the time of
discharge.
Data collection
Investigative cardiologists and trained research nurses recorded
data on the demographic variables, medical history, therapeutic
procedures, and clinical events of each patient during hospital-
ization. Information was obtained from the medical records and
by direct interview of the patients, family members, and treating
physicians.
Primary endpoints and deﬁnitions
The primary end-point for this study was the development of
dn-DM after survival discharge for AMI. Patients were considered
to have developed dn-DM if any of the following occurred during
the 5-year follow-up period: (1) a clinical diagnosis of DM was
reported. If the investigator or the treating physician reported
a clinical diagnosis of DM,  or if the patients had started chronic
medical treatment with insulin or an oral anti-diabetic agent; or
(2) if the patient had an HbA1c level of ≥6.5% during the 5-year
follow-up period.
Hypertension was  deﬁned as a history of systolic blood
pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or
antihypertensive therapy. Hyperlipidemia was  deﬁned as fasting
total cholesterol ≥ 220 mg/dl, fasting triglycerides ≥ 150 mg/dl, or
antilipidemial therapy. Smoking was deﬁned as currently smoking
or a history of smoking. A history of DM was deﬁned as patients
who had been diagnosed or were being treated for DM (diet,
tablets, or insulin) before admission, during hospitalization, or at
the time of discharge, and as those patients with an admission
HbA1c of >6.0%. In this study, the HbA1c values of patients were
converted by calculating formula of the National Glycohemoglobin
Standardization Program (NGSP) from Japanese conventional
HbA1c value (JDS value).
Statistical analysis
Data are expressed as the mean ± standard deviation (SD) or
median with 25th and 75th percentiles for continuous variables,
while qualitative data are presented as numbers or percentages.
Differences in continuous variables between groups were com-
pared by the Student’s t-test or the Mann–Whitney U-test, while
categorical variables were compared by the chi-square test. To
assess the association between patient characteristics and AH, we
used an adjusted logistic regression model. Survival curves were
constructed by the Kaplan–Meier method and the signiﬁcance of
differences in survival was  assessed by the log-rank test. To reduce
the impact of treatment selection bias and potential confound-
ing, a Cox proportional-hazards regression model was  used during
the assessment of predictors for the development of dn-DM and
for the association between the reduced incidence of develop-
ment of dn-DM and treatment with ACE inhibitors or ARBs. The
variables included in the regression model were age, male gen-
der, body mass index (BMI), history of hypertension, history of
hyperlipidemia, smoking, Killip classiﬁcation on hospital admis-
sion, HbA1c on admission, peak CK of >3000 IU/L, ST-elevation MI,
and major medication at hospital discharge. Data analysis was  per-
formed using SPSS statistical software (version 19.0; SPSS Japan
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Table 1
Clinical baseline characteristics of study patients with and without acute hyperglycemia.
Variable Acute hyperglycemia (−) Acute hyperglycemia (+) p-Value
Plasma glucose < 200 mg/dl (N = 1360) Plasma glucose ≥ 200 mg/dl (N = 133)
Clinical characteristic
Men  (%) 76.2 68.4 0.057
Age  (years) 65.3 ± 12.0 68.1 ± 11.3 0.008
Body  mass index (kg/m2) 23.4 ± 3.5 22.6 ± 3.2 0.016
Hypertension (%) 54.6 57.3 0.582
Hyperlipidemia (%) 41.8 34.6 0.135
Smoking (%) 64.7 57.3 0.105
Familial history of diabetes (%) 16.8 17.5 0.876
ST elevation myocardial infarction (%) 83.8 87.1 0.383
Killip  classiﬁcation ≥ II (%) 10.2 36.0 <0.001
Peak  CK > 3000 IU/L (%) 35.6 56.3 <0.001
Onset  to admission (h) 3.5 (1.5–13.5) 2.0 (1.0–7.4) 0.393
HbA1c at admission (%) 5.54 ± 0.3 5.51 ± 0.3 0.387
Glucose levels at admission (mg/dl) 129.9 ± 27.7 258.5 ± 62.0 <0.001
Fasting glucose levels at discharge (mg/dl) 92.8 ± 14.3 96.8 ± 30.0 0.124
Re-perfusion therapy (%) 89.9 93.2 0.283
PCI  (%) 86.9 91.7 0.132
Medications at hospital discharge
Antiplatelets (%) 98.0 99.2 0.506
ACE  inhibitors or ARBs (%) 75.6 72.9 0.527
Beta-blockers (%) 48.0 51.9 0.414
Ca-antagonists (%) 18.7 10.5 0.018
Statins (%) 36.9 30.1 0.131
Diuretics (%) 24.4 42.9 <0.001
Nitrates (%) 36.9 51.1 0.002
D or dichotomous variables.
C ntervention; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor, blocker.
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Table 2
Patient characteristics associated with acute hyperglycemia on admission after
acute myocardial infarction.
Characteristic Association with acute hyperglycemia
Odds ratio 95% CI p-Value
Men  0.843 0.489–1.451 0.537
Age  (per 1 year of age) 1.011 0.989–1.034 0.345
Body mass index (per 1 kg/m2) 0.950 0.887–1.019 0.151
Hypertension 1.173 0.747–1.841 0.489
Hyperlipidemia 0.903 0.572–1.424 0.660
Smoking 1.071 0.643–1.783 0.793
ST  elevation myocardial infarction 1.067 0.560–2.032 0.844
Killip classiﬁcation 1.909 1.502–2.425 <0.001
Peak CK > 3000 IU/L 1.831 1.164–2.879 0.009
Onset to admission time (per 1 h) 0.989 0.974–1.005 0.186
HbA1c at admission (per 0.1%) 0.967 0.905–1.035 0.334
CK, creatine kinase; HbA1c, glycated hemoglobin A1c.ata are shown as median or mean ± SD for continuous variables and percentages f
K,  creatine kinase; HbA1c, glycated hemoglobin A1c; PCI, percutaneous coronary i
nc., Tokyo, Japan). For all analyses, statistical signiﬁcance was
eﬁned as p < 0.05 and p for interaction < 0.1.
esults
Of the total 1493 AMI patients included in the study, 196 (13.1%)
ere newly diagnosed with DM during the mean follow-up period
f 924 days. The clinical characteristics and major medications at
ospital discharge for the study patients based on the occurrence
f AH are listed in Table 1. Patients with AH were older, had a
ower BMI, a higher prevalence of Killip classiﬁcation on admission
II, and larger MI,  as determined by peak CK, than those with-
ut AH. Furthermore, patients with AH were more often treated
ith diuretics and nitrates at discharge, but were prescribed Ca-
ntagonists signiﬁcantly less often. No differences between the
wo AMI  patient groups were seen in HbA1c on admission, or fas-
ing glucose levels and other medications at discharge. In adjusted
ogistic regression analysis, AH was associated with higher Killip
lassiﬁcation and larger MI,  but was not associated with HbA1c on
dmission (Table 2).
Fig. 1 presents Kaplan–Meier curves for the development of dn-
M in patients with and without AH. Patients with AH had a higher
ncidence of dn-DM than those in the non-AH group (24.8% vs 12.0%,
espectively; log-rank test p < 0.001).
In the multivariate analysis, AH was found to be an indepen-
ent predictor for the development of dn-DM in post-AMI patients
Table 3). After adjustment for age and male gender (Model 1), the
azard ratio (HR) was 2.210 (95% CI 1.518–3.219). With further
djustment for age, male gender, history of hypertension, hyper-
ipidemia, smoking, HbA1c on admission, BMI, Killip classiﬁcation
n hospital admission, peak CK > 3000 IU/L, ST-elevation MI,  and
edication at hospital discharge (Model 4), AH remained as an
ndependent predictor for the development of dn-DM in post-AMI
atients (HR 1.776, 95% CI 1.092–2.890, p = 0.021).
To minimize the inﬂuence of pre-existing DM on the apparent
redictive value of hyperglycemia, we also analyzed the association
etween AH and dn-DM according to HbA1c levels on admission,
Fig. 1. Kaplan–Meier estimates for the development of de novo diabetes mellitus in
acute myocardial infarction patients with and without acute hyperglycemia.
M. Usami et al. / Journal of Cardi
Table  3
Association between acute hyperglycemia and development of de novo diabetes
mellitus.
Development of de novo diabetes mellitus
Hazard ratio 95% CI p-Value
Univariate 2.069 1.423–3.008 <0.001
Multivariate
Model 1 2.210 1.518–3.219 <0.001
Model 2 2.148 1.423–3.240 <0.001
Model 3 1.665 1.032–2.686 0.037
Model 4 1.776 1.092–2.890 0.021
Model 1: adjusted for age and male gender; Model 2: adjusted for age, male gen-
der, history of hypertension, hyperlipidemia, smoking, HbA1c on admission, and
body mass index; Model 3, adjusted for age, male gender, history of hypertension,
hyperlipidemia, smoking, HbA1c on admission, body mass index, Killip classiﬁcation
on  hospital admission, peak CK > 3000 IU/L, and ST-elevation myocardial infarction;
Model 4, adjusted for age, male gender, history of hypertension, hyperlipidemia,
smoking, HbA1c on admission, body mass index, Killip classiﬁcation on hospital
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t  hospital discharge.
I, conﬁdence interval; CK, creatine kinase; HbA1c, glycated hemoglobin A1c.
sing a value of 5.6% (Fig. 2). In post-AMI patients with lower HbA1c
evels (<5.6%), a stronger association was detected between AH
nd the development of dn-DM than in those patients with higher
bA1c levels (≥5.6%) (adjusted p for interaction = 0.062).
We next evaluated the pharmacological modiﬁcation of this
mpact in post-AMI patients and found that inhibition of the
enin–angiotensin system (RAS) might have attenuated the risk of
H on the development of dn-DM after AMI. Table 4 shows the
linical characteristics, as well as the treatments and major medi-
ations at hospital discharge, of AH group patients treated with and
ithout RAS inhibitors, such as ACE inhibitors and ARBs, at hospi-
al discharge. Patients treated with RAS inhibitors at discharge had
lightly lower HbA1c levels on admission than AH group patients
ot receiving RAS inhibitors. However, no differences between the
wo groups were detected in the other examined parameters.
Fig. 3 presents Kaplan–Meier curves for the development of
n-DM among post-AMI patients treated with and without RAS
nhibitors according to the prevalence of AH. In patients with-
ut AH, no differences in the development of dn-DM were found
ased on treatment with RAS inhibitors. In contrast, in patients
ig. 2. Kaplan–Meier estimates for the development of de novo diabetes mellitus in acute m
y  glycated hemoglobin (HbA1c) values on admission of 5.6%.ology 63 (2014) 274–280 277
with AH, a lower incidence of dn-DM was  detected in those treated
with RAS inhibitors at discharge than those without (20.6% vs
36.1%, respectively; log-rank test p = 0.010). The multivariate anal-
ysis revealed that treatment with RAS inhibitors was associated
with a reduced incidence of development of dn-DM (HR 0.397,
95% CI 0.171–0.921, p = 0.031) in AH group patients, whereas no
association was  found in non-AH group patients (adjusted p for
interaction = 0.055; Table 5).
Discussion
The present study revealed that AH after the onset of AMI  may  be
an independent predictor of dn-DM development in non-diabetic
AMI  patients. Our ﬁndings also suggest that inhibition of the RAS
may  attenuate the risk of dn-DM in the secondary prevention set-
ting after AMI  with AH.
AH is a common feature during the early phase after AMI, even
in non-diabetic patients [13,14,18]. A number of studies have iden-
tiﬁed an association between AH and poor prognosis following
AMI, particularly in non-diabetic patients [13–15,17,23,24]. AH
is reported to be a manifestation of transient abnormal glucose
metabolism that is possibly induced by the acute release of cate-
cholamine, cortisol, and cytokines in the acute stage of MI  [25–33].
Although several studies have reported a relationship between AH
and adverse clinical outcomes after AMI, the association between
AH and development of dn-DM after survival discharge for AMI
was unclear prior to the present study. In the present study, the
univariate analysis revealed that patients with AH had a 2.1-fold
higher risk for the development of dn-DM. Furthermore, mul-
tivariate analysis demonstrated that this association remained
unchanged in four different statistical models, even after adjust-
ment for age, male gender, history of hypertension, hyperlipidemia,
smoking, HbA1c and Killip classiﬁcation on admission, BMI, peak
CK > 3000 IU/L, ST-elevation MI,  and medication at hospital dis-
charge, which included statins, ACE inhibitors, ARBs, beta-blockers,
nitrates, and diuretics. Based on these analyses, we  may  conclude
that AH during the acute stage of AMI  is a useful predictor for the
development of dn-DM in patients without a previous diagnosis of
DM.
Although the mechanisms underlying the relationship between
AH and dn-DM in post-AMI patients remain unclear, there are
yocardial infarction patients with and without acute hyperglycemia, as determined
278 M. Usami et al. / Journal of Cardiology 63 (2014) 274–280
Table 4
Clinical baseline characteristics of acute myocardial infarction patients with acute hyperglycemia based on ACE inhibitors or ARBs at discharge.
Variable Acute hyperglycemia (+) Acute hyperglycemia (+) p-Value
ACE  inhibitors or ARBs (−) (N = 36) ACE inhibitors or ARBs (+) (N = 97)
Clinical characteristic
Men  (%) 69.4 68.0 1.000
Age  (years) 69.1 ± 13.4 67.7 ± 10.5 0.519
Body  mass index (kg/m2) 22.6 ± 4.0 22.7 ± 2.9 0.934
Hypertension (%) 47.2 61.1 0.170
Hyperlipidemia (%) 25.0 38.3 0.216
Smoking (%) 61.8 55.7 0.554
Familial history of diabetes (%) 5.6 21.0 0.172
ST elevation myocardial infarction (%) 91.4 85.6 0.558
Killip  classiﬁcation ≥ II (%) 41.2 34.1 0.905
Peak  CK > 3000 IU/L (%) 62.5 54.0 0.532
Onset  to admission (h) 1.8 (1.0–8.5) 2.0 (1.0–5.7) 0.987
HbA1c at admission (%) 5.6 ± 0.3 5.5 ± 0.3 0.039
Glucose levels at admission (mg/dl) 257.9 ± 65.7 258.7 ± 60.9 0.949
Fasting glucose levels at discharge (mg/dl) 102.4 ± 33.3 94.2 ± 15.8 0.132
Re-perfusion therapy (%) 94.4 92.8 1.000
PCI  (%) 91.7 91.8 1.000
Medications at hospital discharge
Antiplatelets (%) 97.2 100.0 0.271
Beta-blockers (%) 50.0 52.6 0.847
Ca-antagonists (%) 13.9 9.3 0.526
Statins (%) 27.8 30.9 0.833
Diuretics (%) 47.2 41.2 0.559
Nitrates (%) 58.3 48.5 0.335
Data are shown as median or mean ± SD for continuous variables and percentages for dichotomous variables.
CK,  creatine kinase; PCI, percutaneous coronary intervention; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HbA1c, glycated hemoglobin A1c.
Fig. 3. Kaplan–Meier estimates for the development of de novo diabetes mellitus in acute myocardial infarction patients treated with and without renin–angiotensin system
inhibitors based on to the prevalence of acute hyperglycemia. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Table 5
Association between ACE inhibitors/ARBs and development of de novo diabetes mellitus.
Development of de novo diabetes mellitus
Admission glucose < 200 mg/dl Admission glucose ≥ 200 mg/dl p for interaction
Hazard ratio 95% CI p-Value Hazard ratio 95% CI p-Value
Univariate 1.359 0.923–2.000 0.120 0.411 0.203–0.829 0.013
Multivariate
Model  1 1.260 0.854–1.859 0.245 0.411 0.203–0.832 0.013
Model  2 1.247 0.844–1.841 0.268 0.428 0.204–0.900 0.025
Model  3 1.031 0.687–1.546 0.884 0.397 0.171–0.921 0.031 0.055
Model 1: adjusted for age and male gender; Model 2: adjusted for age, male gender, and HbA1c on admission; Model 3: adjusted for age, male gender, HbA1c on admission,
history of hypertension, hyperlipidemia, smoking, and body mass index.
CI, conﬁdence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HbA1c, glycated hemoglobin A1c.
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everal possible explanations. First, the occurrence of AH in AMI
atients without a history of DM might have reﬂected previously
ndiagnosed DM or preexisting impaired glucose tolerance. In the
resent study, to minimize these possibilities, we excluded patients
ith an admission HbA1c of >6.0%, regardless of their DM history.
n addition, our analysis revealed that there was a stronger associ-
tion between AH and the development of dn-DM in AMI  patients
ith lower HbA1c levels (<5.6%) than those with higher HbA1c
evels (≥5.6%). Because the interaction between HbA1c levels and
H was statistically signiﬁcant (p value for interaction = 0.062), AH
s considered to be particularly associated with the development
f dn-DM in patients with lower HbA1c values. Thus, the observed
elationship between dn-DM and stress-induced hyperglycemia in
he post-AMI study patients was not likely a result of preexisting
lucometabolic abnormalities, but was likely due to other mech-
nisms associated with AH. Furthermore, Ishihara et al. showed
hat 53% of the patients with admission glucose ≥11.1 mmol/L did
ot have DM in a study investigating the association between AH
nd results of glucose tolerance tests in AMI  patients who  had
ot been previously diagnosed as having DM [34]. Thus, although
he presence of undiagnosed DM may  be associated with AH in
on-diabetic AMI  patients, a positive association between AH and
ew onset of DM cannot be explained by only the presence of
ndiagnosed DM. Second, it is possible that sustained damage to
lycometabolic systems might have resulted in the development
f dn-DM in the post-AMI patients. Wallander et al. [35] suggested
hat early beta cell dysfunction and insulin resistance in AMI
atients persisted up to 12 months after hospital discharge. In
ritical illness, the stress response is accompanied by the release
f cortisol, catecholamines, glucagon, and growth hormone, which
ay  induce continuous glucometabolic abnormalities [25–33].
hus, in AMI patients with chronic heart failure, continuous
elease of cortisol, catecholamines, glucagon, and growth hormone
ight have induced glucometabolic abnormalities. Furthermore,
roinﬂammatory cytokines, such as interleukin-1 and tumor
ecrosis factor alpha, cause hyperglycemia and peripheral insulin
esistance by promoting similar hormones or by altering insulin
eceptor signaling [36,37]. On the other hand, it is well known that
cute hyperglycemia or chronic heart failure increases oxidative
tress. Evans et al. reported that oxidative stress plays a key
ole in causing insulin resistance and beta cell dysfunction [38].
herefore, a continuous increase in oxidative stress might have
nduced sustained damage to glycometabolic systems, causing
eta cell dysfunction or insulin resistance in AMI  patients with
hronic heart failure. Taken together, these lines of evidence
uggest that sustained endocrine and metabolic changes might
nduce the development of dn-DM after AMI.
Another novel ﬁnding of the present study was  that RAS inhibi-
ion was associated with reduced incidence of dn-DM in post-AMI
atients with AH after survival discharge. Although the beneﬁcial
mpacts of RAS inhibitors, such as ACE inhibitors and ARBs, on the
revention of new-onset type 2 DM have been reported in several
linical trials involving patients with hypertension, chronic heart
ailure, or stable coronary artery disease [39–41], data are limited
n the secondary prevention setting after AMI. Thus, our present
ndings may  provide important clinical information, as we found
hat treatment with RAS inhibitors at discharge was associated with
 decreased incidence of dn-DM development in non-diabetic AMI
atients with admission AH. It has been reported that angiotensin
I increases hepatic glucose production and decreases insulin sensi-
ivity, whereas ACE inhibitors and ARBs increase insulin sensitivity
42,43]. Therefore, the treatment of AMI  patients with AH on admis-
ion using RAS inhibitors might have improved insulin sensitivity
fter AMI  and decrease the incidence of dn-DM development.
owever, further investigations are warranted to examine the ben-
ﬁcial impacts and mechanisms of RAS inhibitors for reducing theology 63 (2014) 274–280 279
incidence of dn-DM development after discharge in AMI patients
presenting with AH.
Limitations
A few limitations of this study warrant mention. First, we  did
not have information regarding oral glucose tolerance tests (OGTT).
Several studies have shown that abnormal glucose tolerance diag-
nosed by OGTT is common in AMI  patients without a previous
diagnosis of DM [9,44]. In the present study, we were not able
to perform an OGTT to identify glucometabolic abnormalities in
patients with AMI. Thus, it is possible that patients with undiag-
nosed DM were included in the study population. However, the
impact of undiagnosed diabetic patients on the primary outcome
was likely minimal, because the ﬁndings were unchanged when
we employed an inclusion criterion of HbA1c levels on admission
of 5.2% or lower, as this value reportedly excludes diabetic patients
[45] (data not shown). Second, we did not have the data on the time
elapsed from the last meal. The time elapsed from the last meal to
blood collection likely affected plasma glucose levels. Third, this
study was observational and was not randomized; thus, there may
have been potential confounding factors, even after adjustment
with baseline clinical and angiographic characteristics. However,
our subjects may  reﬂect the ‘real world’ population because they
were typical, consecutively enrolled AMI  patients hospitalized in
an urban area of Japan.
Conclusions
The ﬁndings from the present study indicate that AH might not
only be a marker of systemic stress induced by AMI, but also a
predictor of the risk for dn-DM in non-diabetic AMI  patients. Fur-
thermore, we revealed that inhibition of the RAS may  attenuate the
risk of dn-DM in post-AMI patients with AH.
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